TOPLINE:

In patients with hepatocellular carcinoma (HCC) who received immunotherapy, median overall survival was 20.6 months in those with preserved liver function. Metabolic dysfunction-associated steatotic liver disease, liver function metrics, and presence of varices independently predicted survival outcomes.

METHODOLOGY:

Recent clinical trials have demonstrated the superiority of immunotherapy-based combinations over multikinase inhibitors in treating HCC. The combination of atezolizumab plus bevacizumab was the first treatment to show superiority over sorafenib, followed by successful trials of dual immunotherapy regimens.

A Brazilian multicenter observational study included 163 patients with unresectable or metastatic HCC treated with immunotherapy between August 2020 and March 2

See Full Page